Latest News on VCEL

Financial News Based On Company


Advertisement
Advertisement

Vericel (VCEL) principal accounting officer exercises options and sells all 1,885 shares.

https://www.stocktitan.net/sec-filings/VCEL/form-4-vericel-corp-insider-trading-activity-352bca64d84b.html
Jonathan Siegal, Principal Accounting Officer at Vericel Corp (VCEL), exercised options for 1,885 common shares on November 13, 2026, and subsequently sold all those shares on the same day. The transactions involved three lots with varying exercise prices and sale prices, resulting in an approximate pre-tax spread of $46,000. These transactions were exempt under Rule 16b-3(d) and Rule 16b-3(c) and no Rule 10b5-1 plan was reported.

Vericel Corporation (VCEL) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/VCEL/seasonality/
The article displays a seasonal returns chart for Vericel Corporation (VCEL), showing average monthly price returns from 2016 to 2026. It includes current stock data such as the real-time price, closing price, and after-hours trading information for VCEL.

Form 144 Vericel Corp For: 14 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-vericel-corp-for-14-november-93CH-4958682
This article from Investing.com announces the filing of Form 144 for Vericel Corp on November 14. Form 144 is a notice filed with the SEC by an affiliate of a company to announce their intention to sell restricted securities. The article provides minimal detail beyond this announcement and includes the stock symbol VCEL.

Vericel director Kevin McLaughlin sells $412,720 in stock

https://www.investing.com/news/insider-trading-news/vericel-director-kevin-mclaughlin-sells-412720-in-stock-93CH-5023871
Vericel director Kevin McLaughlin sold 7,000 shares of the company's common stock for $412,720 on November 10, 2026, executed via a Rule 10b5-1 trading plan. This sale occurred while the stock was trading near its 52-week high after a 75% surge. Concurrently, McLaughlin acquired 7,000 shares by exercising stock options for $91,350 and now directly holds 18,300 shares.

Officer Jonathan D. Siegal proposes selling 1,885 Vericel (VCEL) shares.

https://www.stocktitan.net/sec-filings/VCEL/144-vericel-corp-sec-filing-b99bc4c8b207.html
Jonathan D. Siegal, an officer at Vericel Corp (VCEL), has filed a notice proposing the sale of 1,885 common shares with an approximate market value of $108,779.53. These shares were acquired through a stock option exercise on November 13, 2026. Siegal had previously sold 1,500 common shares on November 5, 2026, generating gross proceeds of $79,350.
Advertisement

Vericel's Stephens conference presentation will be available as a webcast.

https://www.stocktitan.net/news/VCEL/vericel-to-present-at-the-stephens-annual-investment-conference-on-hsdydupormh0.html
Vericel Corporation announced it will present at the Stephens Annual Investment Conference on November 18, 2026, at 4:30 p.m. ET. A webcast of the presentation will be accessible via the Investor Relations section of the company's website. Vericel specializes in advanced therapies for sports medicine and severe burn care, marketing products like MACI, Epicel, and NexoBrid.

Vericel (VCEL) CFO Mara sells shares under an automatic trading plan after $43.63 option exercises.

https://www.stocktitan.net/sec-filings/VCEL/form-4-vericel-corp-insider-trading-activity-4208f6369e93.html
Vericel Corp.'s CFO, Joseph Anthony Mara Jr., exercised options for 25,008 shares at an exercise price of $43.63 per share across two dates in November 2026. He then sold these shares at $58.26 and $59.75 per share, respectively. These transactions were automatic, carried out under a Rule 10b5-1 trading plan adopted in December 2025.

Vericel CFO Joseph Mara sells $1.46M in shares

https://www.investing.com/news/insider-trading-news/vericel-cfo-joseph-mara-sells-146m-in-shares-93CH-5023885
Vericel CFO Joseph Mara recently sold 25,008 company shares for approximately $1.46 million, with transactions occurring on November 9 and 11, 2026. These sales were conducted under a Rule 10b5-1 trading plan after Mr. Mara acquired the same number of shares through stock option exercises for $1.09 million. The company has seen significant growth, with shares surging nearly 75% over the past six months and a recent strong Q3 2026 earnings report surpassing Wall Street expectations.

Form 4 Vericel Corp Ord: Robert L. MD Zerbe (Director) For: 9 November

https://ca.investing.com/news/stock-market-news/form-4-vericel-corp-ord-robert-l-md-zerbe-director-for-9-november-93CH-4955103
This article reports on a Form 4 filing for Vericel Corp (VCEL) concerning Director Robert L. MD Zerbe, with the transaction date being November 9. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The article provides the basic announcement without further details on the nature of the transaction.

Form 4 Vericel Corp Ord: Kevin F. Mclaughlin (Director) For: 10 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-vericel-corp-ord-kevin-f-mclaughlin-director-for-10-november-93CH-5701535
This article reports on a Form 4 filing for Vericel Corp (VCEL) concerning insider transactions by director Kevin F. Mclaughlin on November 10. The filing, published by Investing.com, indicates an insider trading activity for the specified date. The core content is a brief announcement of this regulatory filing.
Advertisement

Form 4 Vericel Corp Ord: Joseph Anthony Mara Jr (CFO) For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-vericel-corp-ord-joseph-anthony-mara-jr-cfo-for-9-november-93CH-5701555
This article reports on a Form 4 filing for Vericel Corp (VCEL) concerning Joseph Anthony Mara Jr, the company's CFO, for transactions made on November 9th. The Form 4 filing indicates insider trading activity, which is publicly disclosed through the SEC. The article serves as a brief notification of this financial disclosure.

An automatic trading plan drove director Zerbe’s sale of 2,000 Vericel (VCEL) shares at $57.88 each.

https://www.stocktitan.net/sec-filings/VCEL/form-4-vericel-corp-insider-trading-activity-074a60189625.html
Vericel Corp director Robert L. Md Zerbe exercised options for 2,000 common shares at $13.05 each and subsequently sold all 2,000 shares at $57.88 each on November 9, 2026. This transaction was executed automatically under a Rule 10b5-1 trading plan established on May 19, 2026. After the sale, Zerbe holds 32,995 shares of common stock.

Vericel (VCEL) director exercises options at $13.05, sells 7,000 shares at $58.96.

https://www.stocktitan.net/sec-filings/VCEL/form-4-vericel-corp-insider-trading-activity-34f3134825f5.html
Vericel Corp (VCEL) director Kevin F. McLaughlin exercised options for 7,000 shares at $13.05 per share on November 10, 2026, and subsequently sold these shares at $58.96 each. This transaction, resulting in an approximate pre-tax spread of $321,000, was conducted under a Rule 10b5-1 trading plan adopted in May 2025. After the sale, McLaughlin holds 18,300 shares of common stock.

Form 4 Vericel Corp Ord: Joseph Anthony Mara Jr (CFO) For: 9 November

https://uk.investing.com/news/stock-market-news/form-4-vericel-corp-ord-joseph-anthony-mara-jr-cfo-for-9-november-93CH-4979443
This article reports on a Form 4 filing for Vericel Corp (VCEL) concerning Joseph Anthony Mara Jr, the CFO, for transactions made on November 9. Form 4 filings disclose changes in beneficial ownership of securities by company insiders. The brief news item indicates these filings are relevant to the stock market performance of Vericel Corp.

An officer proposes selling 8 Vericel (VCEL) shares valued at $478 after a stock option exercise.

https://www.stocktitan.net/sec-filings/VCEL/144-vericel-corp-sec-filing-c0acbe3dd9fc.html
Joseph Anthony Mara Jr., an Officer of Vericel Corp (VCEL), has proposed selling 8 common shares acquired through a stock option exercise, with an approximate sale date of November 11, 2026, and an aggregate market value of $478. This proposed transaction is detailed in a Form 144 SEC filing. The filing also notes previous sales by Mr. Mara in early November 2026 and indicates a Rule 10b5-1 plan adoption date of December 2, 2025.
Advertisement

Form 144 Vericel Corp For: 11 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-vericel-corp-for-11-november-93CH-4949423
This article from Investing.com announces a Form 144 filing for Vericel Corp (VCEL) on November 11, 2026. The filing indicates insider intent to sell restricted or controlled securities, typically highlighting a significant event for the company's stock. The report includes general market data and related articles but no further details about the specific transaction.

Vericel (VCEL) director proposes selling 7,000 shares under a trading plan adopted in May 2025.

https://www.stocktitan.net/sec-filings/VCEL/144-vericel-corp-sec-filing-f6624f4e1ac1.html
Vericel Corp (VCEL) director Kevin F. McLaughlin has proposed selling 7,000 common shares worth $408,730, with an approximate sale date of November 10, 2026. This proposed sale is part of a Rule 10b5-1 trading plan adopted on May 12, 2025, and the shares were acquired through a cash-paid stock option exercise on the same day as the proposed sale. McLaughlin previously sold 7,000 shares on August 12, 2026, for over $311,000.

Vericel Corporation 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:VCEL) 2026-11-10

https://seekingalpha.com/article/4966175-vericel-corporation-2026-q3-results-earnings-call-presentation
Vericel Corporation has published its slide deck in conjunction with its 2026 Q3 earnings call. The company reported an EPS of $0.27, beating estimates by $0.21, and revenue of $85.37M, representing a 26.47% year-over-year increase and beating estimates by $7.42M. This presentation provides details on their financial performance for the quarter.

An officer proposes another Vericel (VCEL) share sale after selling $1.53M on November 6.

https://www.stocktitan.net/sec-filings/VCEL/144-vericel-corp-sec-filing-2d6ef958417a.html
Vericel officer Joseph A. Mara has filed notice for a proposed sale of 25,000 common shares, valued at approximately $1.46 million, with an approximate sale date of November 9, 2026. This proposed sale follows prior sales by Mara of 21,359 shares on November 5, 2026, and 28,641 shares on November 6, 2026, totaling over $2.6 million in gross proceeds. The shares were acquired through a stock option exercise on November 9, 2026, and the proposed sale falls under a Rule 10b5-1 plan adopted on December 2, 2025.

Automatic trading-plan sales total 50,000 shares for Vericel (VCEL) CFO.

https://www.stocktitan.net/sec-filings/VCEL/form-4-vericel-corp-insider-trading-activity-87e2d9328be2.html
Vericel Corp's Chief Financial Officer, Joseph Anthony Mara Jr., exercised options and subsequently sold a total of 50,000 common shares on November 5 and 6, 2026. These transactions, which involved significant pre-tax spread, were automatic sales executed under a Rule 10b5-1 trading plan established on December 2, 2025. The sales represented 75.5% of his position.
Advertisement

HC Wainwright and Truist raise Vericel price targets, maintain Buy

https://scanx.trade/stock-market-news/companies/hc-wainwright-raises-vericel-price-target-75-maintains-buy/55513032
HC Wainwright & Co. and Truist Securities have both increased their price targets for Vericel Corp (VCEL) while maintaining a Buy rating. HC Wainwright raised its target to $75 from $72, and Truist Securities significantly increased its target to $65 from $52, reflecting continued confidence in the company's outlook and strong performance in its MACI and Burn Care franchises.

Earnings Beat: Vericel Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcel/vericel/news/earnings-beat-vericel-corporation-just-beat-analyst-forecast
Vericel Corporation reported strong third-quarter results, exceeding revenue and earnings per share forecasts significantly. Despite the beat, analysts have largely maintained their 2027 revenue and EPS estimates, indicating no major change in their long-term outlook for the company. The consensus price target for Vericel also remains stable at US$59.71, though the company's projected revenue growth is expected to be slower than the wider industry.

Vericel Corp (ATQP.SG) Seasonal returns chart - Yahoo Finance

https://sg.finance.yahoo.com/quote/ATQP.SG/seasonality/
This article from Yahoo Finance displays a seasonal returns chart for Vericel Corp (ATQP.SG), showing its average monthly price return from 2016 to 2026. The page also provides summary information, news, statistics, and financial data for the company, alongside various market indices.

December 2, 2025 is the updated plan adoption date for a proposed $1.53M officer sale at Vericel (VCEL).

https://www.stocktitan.net/sec-filings/VCEL/144-a-vericel-corp-sec-filing-c85b0c859c37.html
An amended Rule 144 notice for Vericel Corp (VCEL) details a proposed sale of 28,641 common shares, valued at $1,529,937.78, by officer Mara Joseph Anthony Jr. The filing also notes an updated Plan Adoption Date of December 2, 2025, and mentions a separate past sale of 21,359 common shares by Joseph A. Mara on November 5, 2026. Fidelity Brokerage Services LLC is listed as the broker, with the shares acquired through a stock option exercise.

An officer proposes a Vericel (VCEL) share sale, with $1.14M in sales also reported.

https://www.stocktitan.net/sec-filings/VCEL/144-vericel-corp-sec-filing-e252e8678a14.html
Vericel officer Joseph A. Mara has proposed the sale of 28,641 common shares valued at $1,529,937.78 through Fidelity Brokerage Services LLC. Additionally, a sale of 21,359 common shares, worth $1,144,079.15, was reported on November 5, 2026. These transactions involve shares acquired through a stock option exercise, as detailed in a Form 144 SEC filing.
Advertisement

Vericel Corp (ATQP.MU) Seasonal returns chart - Yahoo Finance

https://sg.finance.yahoo.com/quote/ATQP.MU/seasonality/
The article presents a seasonal returns chart for Vericel Corp (ATQP.MU), showing the average monthly price return from 2016 to 2026. As of the data provided, Vericel Corp's stock was trading at 52.50 EUR, down 0.94%. The page also displays current market indices for Singapore, US, Europe, and Asia.

Vericel Corp (ATQP.DU) Seasonal Returns Chart

https://ca.finance.yahoo.com/quote/ATQP.DU/seasonality/
This article provides a seasonal returns chart for Vericel Corp (ATQP.DU), showing the average monthly price return from 2021 to 2026. The data is presented with a delayed quote from the Dusseldorf exchange, indicating the stock's performance.

After a stock option exercise, a Vericel (VCEL) officer proposes selling shares.

https://www.stocktitan.net/sec-filings/VCEL/144-vericel-corp-sec-filing-2a9b57e39540.html
Vericel Corp (VCEL) officer Joseph Anthony Mara Jr has proposed selling 21,359 common shares, valued at approximately $1.14 million, acquired through a stock option exercise. The proposed sale date is November 5, 2026, and the shares will be sold via Fidelity Brokerage Services LLC on NASDAQ. This Form 144 filing indicates an insider's intent to sell shares after acquisition.

After selling 2,500 shares, Vericel (VCEL) director proposes selling 3,000 more.

https://www.stocktitan.net/sec-filings/VCEL/144-vericel-corp-sec-filing-bed5158e62c7.html
Vericel Corp (VCEL) director Robert L. Zerbe filed a Form 144 notice proposing to sell 3,000 common shares with a market value of $156,682.29. These shares were acquired through a stock option exercise on November 5, 2026. The filing also disclosed that Zerbe previously sold 2,500 common shares for $113,502 on November 4, 2026.

Vericel Corp (VCEL) Q3 2026 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/markets-news/motley/8681790/vericel-corp-vcel-q3-2026-earnings-call-transcript/
Vericel Corporation (VCEL) reported a strong third quarter in 2026, with total revenue reaching $85.4 million, a 26% increase year-over-year, driven by record performance in both its MACI and burn care franchises. The company raised its full-year total revenue guidance to $344 million-$346 million and adjusted EBITDA margin guidance to approximately 28%, reflecting sustained growth, increased profitability, and robust underlying business fundamentals. Management highlighted the positive impact of sales force expansion, MACI Arthro adoption, and commercial excellence initiatives, anticipating continued strong performance into 2027 and beyond, with ongoing international expansion and new indication developments.
Advertisement

An officer proposes selling 1,500 Vericel (VCEL) shares acquired through stock options.

https://www.stocktitan.net/sec-filings/VCEL/144-vericel-corp-sec-filing-242fe484bbf7.html
Jonathan D. Siegal, an officer at Vericel Corp (VCEL), has filed a Form 144 notice indicating his intent to sell 1,500 shares of common stock. These shares, valued at $79,350.00, were acquired through a stock option exercise on November 5, 2026. The proposed sale date is also November 5, 2026, and the transaction is classified as neutral in terms of filing impact and sentiment.

Form 144 Vericel Corp Filed by: SIEGAL JONATHAN

https://www.streetinsider.com/SEC+Filings/Form+144+Vericel+Corp+Filed+by%3A+SIEGAL+JONATHAN/27298923.html
Jonathan Siegal, an officer at Vericel Corp, has filed a Form 144 indicating a proposed sale of 1,500 shares of common stock. The securities were acquired on November 5, 2026, through a stock option exercise from the issuer and will be sold on NASDAQ by Fidelity Brokerage Services LLC. The aggregate market value of the shares is $79,350.00.

Vericel Delivers Its Strongest Beat-And-Raise Of 2026, But Burn Care Spike And A Cautious 2027 Signal Temper The Story

https://finviz.com/news/417305/vericel-delivers-its-strongest-beat-and-raise-of-2026-but-burn-care-spike-and-a-cautious-2027-signal-temper-the-story
Vericel (NASDAQ: VCEL) exceeded third-quarter earnings and revenue estimates significantly, prompting management to raise full-year revenue and adjusted EBITDA margin guidance. While the company saw strong growth in its MACI product line, a substantial portion of the beat came from an unpredictable spike in its Burn Care franchise. Investors are left with a cautious outlook for 2027, tempering the overall positive news despite improved fundamental performance.

Vericel Corp Ord earnings beat by $0.21, revenue topped estimates

https://www.investing.com/news/earnings/vericel-corp-ord-earnings-beat-by-021-revenue-topped-estimates-5004436
Vericel Corp Ord (NASDAQ: VCEL) reported strong third-quarter results, exceeding analyst estimates for both EPS and revenue. The company posted an EPS of $0.27 against an estimated $0.06, and revenue of $85.37M, surpassing the consensus of $77.95M. Furthermore, Vericel provided optimistic full-year 2026 revenue guidance, projecting $344.00M-$346.00M, above the analyst consensus of $336.20M.

Vericel Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62920834/vericel-q3-2026-earnings-call-transcript
Vericel Corporation reported record third-quarter revenue of over $85 million, a 26% increase year-over-year, significantly exceeding guidance and leading to raised full-year revenue guidance of $344-$346 million. The company saw strong performance across its MACI and Burn Care franchises, with MACI achieving record revenue of over $67 million and Burn Care increasing by 52%. Vericel is also preparing for potential international expansion and continued investments in sales force and commercial initiatives, anticipating sustained growth and profitability.
Advertisement

Vericel Revenue Rises 26% to $85.4 Million, Raises 2026 Guidance

https://www.tradingview.com/news/tradingview:52e7c765f17eb:0-vericel-revenue-rises-26-to-85-4-million-raises-2026-guidance/
Vericel (VCEL) reported a 26% year-over-year revenue increase to $85.4 million in Q3 2026, with net income reaching $14.2 million and adjusted EBITDA growing by 48% to $25.2 million. The company raised its full-year revenue guidance to $344 million–$346 million and adjusted EBITDA margin guidance to 28%. Key growth drivers included strong performance in MACI and Burn Care segments, with record quarterly revenue for Epicel and NexoBrid.

Vericel Director Robert L. Zerbe to Sell 2,500 Shares via Rule 144 Filing

https://kalkinemedia.com/us/news/announcements/vericel-director-robert-l-zerbe-to-sell-2500-shares-via-rule-144-filing
Vericel Corp Director Robert L. Zerbe, M.D., has filed a Form 144 notice to sell 2,500 common shares of Vericel stock, valued at $113,501.89. These shares were acquired through a stock option exercise on November 4, 2026, and the sale will be conducted on NASDAQ under a pre-established Rule 10b5-1 trading plan. This transaction marks Zerbe's first sale of Vericel securities in the past three months.

Vericel Corporation (VCEL) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_5967_QuantitativeReport_1792540800000
Vericel Corporation (VCEL) is a commercial-stage biopharmaceutical company focused on sports medicine and severe burn care. Argus recently raised its target price for VCEL to $43.00, up from its current price of $40.26, indicating a positive outlook for the stock. This update comes with the recommendation to upgrade for premium research reports for detailed insights.

VCEL Maintains Rating by Truist Securities -- Price Target Lowered to $52

https://www.gurufocus.com/news/9123841/vcel-maintains-rating-by-truist-securities-price-target-lowered-to-52
Truist Securities has maintained a 'Buy' rating for Vericel (VCEL) but lowered its price target to $52 from $58. Despite this adjustment, GuruFocus calculates VCEL as 28.2% undervalued, with a current price of $40.17 against a GF Value™ of $55.93. The company holds a strong GF Score™ of 82/100, though insider activity shows significant sales, suggesting investors should monitor this closely.

Vericel Corp. (ATQP.SG) Q1 FY2026 earnings call transcript

https://finance.yahoo.com/quote/ATQP.SG/earnings/ATQP.SG-Q1-2026-earnings_call-571887.html
Vericel Corporation reported strong Q1 FY2026 results, with total revenue increasing by 30% year-over-year to $68.4 million and adjusted EBITDA nearly tripling to $9.6 million. The company's gross margin also expanded by over 300 basis points. Following this performance, management raised its full-year revenue guidance to $326 million-$336 million, citing momentum in MACI and Burn Care products, robust cash generation, and successful strategic execution.
Advertisement

Vericel Corporation (VCEL) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_5967_QuantitativeReport_1791331200000
Argus has lowered its target price for Vericel Corporation (VCEL) to $42.00. The company, a biopharmaceutical firm, specializes in therapies for sports medicine and severe burn care markets. This update is part of a series of reports from Argus, also featuring target price adjustments for other companies.

VCEL: Vericel Corp Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/VCEL
The article provides the latest stock price for Vericel Corp (VCEL) which closed at $40.74, up 1.72% for the day. It includes a sentiment indicator showing "Bearish Sentiment" and displays recent posts from a user "Pro_From_Dover" expressing frustration about the stock's performance. The posts highlight a perceived lack of stamina and consistent downward trends during trading hours.

Vericel Corporation (VCEL) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/VCEL/
Vericel Corporation (VCEL) stock closed at $40.74, up 1.72%, on October 7. The biopharmaceutical company specializes in cellular therapies for sports medicine and severe burn care, marketing products like MACI, Epicel, and NexoBrid. Analysts have an average target price of $60.57 for VCEL, with the latest rating from TD Cowen maintaining a Buy and raising the price target to $58.

Vericel Corporation at Morgan Stanley Global Healthcare Conference Transcript

https://www.gurufocus.com/stock/VCEL/transcripts/9083048
This article provides the transcript of Vericel Corporation's presentation at the Morgan Stanley Global Healthcare Conference on September 15, 2026. CEO Nick Colangelo and CFO Joe Mara discussed Macy, their lead product for cartilage repair, including updates on its international launch preparations and a trial for ankle application. The conference provided an opportunity to highlight ongoing initiatives driving the company's growth.

Vericel to Present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026

https://www.marketscreener.com/news/vericel-to-present-at-the-24th-annual-morgan-stanley-global-healthcare-conference-on-tuesday-septem-ce785bd8dc8df025
Vericel Corporation announced it will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026. A webcast of the presentation will be accessible on the investor relations section of the company's website. Vericel is a leader in advanced therapies for sports medicine and severe burn care, offering products like MACI, Epicel, and licensed NexoBrid.
Advertisement

Morgan Stanley will host Vericel at a healthcare conference Sept. 15

https://www.stocktitan.net/news/VCEL/vericel-to-present-at-the-24th-annual-morgan-stanley-global-qm8mgquazkiy.html
Vericel Corporation (NASDAQ: VCEL) announced it will present at the 24th Annual Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2026. The company, a leader in advanced therapies for sports medicine and severe burn care, will webcast its presentation via its Investor Relations website. Vericel experienced a moderate negative market reaction with a 2.76% decline in its stock price on September 8, 2026, the day of the announcement.

Vericel Number of Employees 2026 | Employee Count & Headcount Data

https://www.reveliolabs.com/companies/vericel/employees
Vericel Corp. (VCEL) had 418 total employees worldwide as of March 2026, marking a 24.2% growth from 337 employees in 2023. The company is actively hiring, with 39 active job postings in 2026, though this represents a 2.5% decline from 2025. Vericel's workforce is concentrated in North America, with an average salary of $145,860, and overall employee sentiment is negative and declining.

Madison Asset Management LLC Acquires Shares of 50,116 Vericel Corporation $VCEL

https://www.marketbeat.com/instant-alerts/filing-madison-asset-management-llc-acquires-shares-of-50116-vericel-corporation-vcel-2026-08-21/
Madison Asset Management LLC has acquired 50,116 shares of Vericel Corporation (NASDAQ:VCEL), valued at approximately $2.23 million, representing a new position for the firm. Other institutional investors like BlackRock Inc. and TimesSquare Capital Management LLC also increased their stakes. The article also details recent insider stock sales by Vericel's CFO and another insider, stock performance data, and updated analyst ratings for VCEL.

Summit Creek Advisors LLC Purchases Shares of 219,312 Vericel Corporation $VCEL

https://www.marketbeat.com/instant-alerts/filing-summit-creek-advisors-llc-purchases-shares-of-219312-vericel-corporation-vcel-2026-08-19/
Summit Creek Advisors LLC has acquired 219,312 shares of Vericel Corporation (NASDAQ:VCEL), valued at approximately $9.76 million, making it their second-largest holding. Other institutions like BlackRock and TimesSquare Capital also initiated new positions, while State Street, GW&K, and Goldman Sachs increased their stakes. Vericel recently reported strong quarterly earnings, exceeding analyst estimates with $77.46 million in revenue and $0.04 EPS.

TimesSquare Capital Management LLC Invests $24.46 Million in Vericel Corporation $VCEL

https://www.marketbeat.com/instant-alerts/filing-timessquare-capital-management-llc-invests-2446-million-in-vericel-corporation-vcel-2026-08-18/
TimesSquare Capital Management LLC has invested $24.46 million in Vericel Corporation (VCEL), acquiring 549,846 shares. Other institutional investors have also increased their holdings, while company insiders sold shares. Analyst sentiment is generally positive, with a "Moderate Buy" consensus and an average price target of $58.40, following strong quarterly earnings that exceeded expectations.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement